Results 211 to 220 of about 156,514 (326)
British Journal of Clinical Pharmacology, EarlyView.Patient‐reported outcomes (PROs) are essential for assessing clinical benefit and tolerability from the patient's perspective. In oncology trials, PRO data analysis often involves responder and time‐to‐event analyses, which depend on predefined thresholds to determine clinically meaningful change.
Anna Margarete Maria Thurner +5 more
wiley +1 more source
Dosing Biologic Drugs for Patients with Obesity: One Size Does NOT Fit All
Arthritis &Rheumatology, Accepted Article.
Stephen J. Balevic +2 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić +7 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Abstract Aims Paroxetine is a selective serotonin reuptake inhibitor (SSRI), approved for treatment of major depressive disorder and anxiety disorders. Some SSRIs are known to prolong the QT interval; however, clinical evidence to establish a lack of association between paroxetine and corrected QT interval (QTc) prolongation is limited. Therefore, this
Sven C. van Dijkman +6 more
wiley +1 more source
Low‐intervention clinical trials in Spain: Do they progress?
British Journal of Clinical Pharmacology, EarlyView.Abstract Aims Low‐Intervention Clinical Trials (LICTs) are generally pragmatic trials that investigate medicinal products already authorized for use. In 2014, simplified regulatory frameworks were introduced for LICTs with the aim of reducing regulatory burden and operational complexity, to foster non‐commercial clinical trials (NCCTs); the mandatory ...
Claudia Erika Delgado‐Espinoza +4 more
wiley +1 more source
The placebo puzzle: Putting together the pieces [PDF]
, 2004 Steve Stewart-Williams
core +1 more source
Risk of gastrointestinal bleeding by specific SSRIs and SNRIs: A systematic review and meta‐analysis
British Journal of Clinical Pharmacology, EarlyView.Aim The purpose of this study is to estimate the risk of gastrointestinal bleeding (GIB) by selective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs) individual agents. Methods A systematic review was conducted for each unique antidepressant (i.e.
Ainhoa Gomez‐Lumbreras +8 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Abstract Aims Population pharmacokinetic (popPK) and pharmacokinetic‐pharmacodynamic (PK/PD) models were developed to support clinical development of nemolizumab, a humanized monoclonal antibody targeting the IL‐31 receptor α, in adolescents and adults with moderate‐to‐severe atopic dermatitis (AD).
Floris Fauchet +17 more
wiley +1 more source